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Background: Twenty-eight treatment-naïve mucopolysaccharidosis II patients (16 months–7.5 years) received 0.5
mg/kg idursulfase weekly for one year in NCT00607386. Serum anti-idursulfase immunoglobulin G antibodies (Abs)
were seen in 68% of patients.
Methods: This post hoc analysis examined the relationship between Ab status, genotype, adverse events (AEs), and
efficacy. Event rate analyses, time-varying proportional hazards (Cox) modeling, and landmark analyses were
performed to evaluate the relationship between Ab status and safety. We calculated the cumulative probability of
AEs by genotype to evaluate the relationship between genotype and safety. Urinary glycosaminoglycan (uGAG)
concentration, index of liver size, and spleen volume were compared by Ab status and genotype.
Safety results: The overall infusion-related AE (IRAE) rate was higher in Ab+ patients than in Ab− ones. However,
the rate was highest before Abs developed, then decreased over time, suggesting that Abs did not confer the risk.
A landmark analysis of patients who were IRAE-naïve at the landmark point found that Ab+ patients were no more
likely to experience post-landmark IRAEs than were Ab− patients. In the genotype analysis, all patients in the
complete deletion/large rearrangement (CD/LR) and frame shift/splice site mutation (FS/SSM) groups seroconverted,
compared with only one-third of patients in the missense mutation (MS) group (p < 0.001). The cumulative probability
of having ≥1 IRAE was 87.5% in the CD/LR group and 46.2% in the MS group, with a shorter time to first IRAE in the
CD/LR group (p = 0.004).
Efficacy results: Ab+ patients had a reduced response to idursulfase for liver size and uGAG concentration, but not for
spleen size. However, when percent change from baseline in liver size and in uGAG level at Week 53 were adjusted
for genotype, the difference was significant only for neutralizing Ab+ groups. In the genotype analysis, the CD/LR and
FS/SSM groups had a reduced response in liver size and uGAG concentration compared with the MS group.
Conclusions: Safety outcomes and spleen size response on idursulfase treatment appeared to be associated with
genotype, not Ab status. Liver size and uGAG response on idursulfase treatment at Week 53 appeared to be associated
with both neutralizing Ab status and genotype.
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Mucopolysaccharidosis II (MPS II, Hunter syndrome;
OMIM 309900) is a rare, X-linked lysosomal storage
disorder caused by a deficiency in the enzyme
iduronate-2-sulfatase (I2S), leading to the accumulation
of glycosaminoglycans (GAGs) within lysosomes [1,2].
Patients generally appear normal at birth, but develop
characteristic, multi-systemic signs and symptoms begin-
ning during early childhood [2,3]. Disease manifestations
progress over time, leading to significant morbidity and
early mortality [4,5]. In addition, about two-thirds of pa-
tients experience progressive cognitive impairment [6];
such patients are said to have the severe phenotype.
Enzyme replacement therapy consists of administra-
tion of the missing enzyme in recombinant form, and
this has been successful in a number of lysosomal stor-
age diseases, such as Fabry, Gaucher, MPS I, MPS II,
MPS IV, and MPS VI [7]. Inevitably, such treatment will
lead to a certain level of immunogenicity in patients
who produce no endogenous enzyme. This has been
most dramatically shown in Pompe disease, where patients
with no cross-reactive immune material (CRIM) have a
high rate of antibody (Ab) production to the exogenously
administered enzyme [8,9], and in MPS IV, where Ab pro-
duction was universally observed in the patients in the
pivotal trial [10]. The real question; however, is not so
much the rate of seroconversion, but the clinical impact of
these Abs, especially of neutralizing antibodies (NAbs),
which would be expected to mitigate the clinical efficacy
of the treatment. In Pompe disease especially, there is
clear evidence that the humoral Ab response in CRIM-
negative patients is associated with worse outcomes [9],
whereas in MPS II and MPS I, the focus has been on the
association between biomarkers and Abs [11,12].
In MPS II, two clinical trials have been performed with
treatment-naïve patients. The first of these studies, TKT-
ELA-024 (NCT00069641), was the topic of a previously
published analysis [11]. This analysis, which comprised
data from 63 patients who received enzyme replacement
therapy with intravenous idursulfase 0.5 mg/kg weekly
in the phase II/III study and/or the extension study ex-
amined the relationship between Ab status and safety
and efficacy outcomes in an attenuated, treatment-naïve
population of patients 5 years of age and older [11]. We
found that Ab positivity did not appear to lessen the clin-
ical response to idursulfase as assessed by the 6-minute
walk test, and patients who were Ab positive (Ab+) did
not appear to have an increased risk of serious adverse
events (SAEs). Infusion-related adverse events (IRAEs)
were about two-fold more likely in patients who became
Ab+ on treatment; however, most of the risk occurred be-
fore Abs developed and could be ameliorated after a first
reaction through subsequent use of previously published
preventative measures [13]. A genotype analysis in the 36patients with available data found that patients with non-
sense or frameshift mutations appeared more likely to de-
velop Abs, to experience IRAEs, and to have a slightly
reduced urinary GAG (uGAG) response than those with
missense mutations (MS). These findings suggest that Abs
are not a driver of clinical outcomes, but instead may be a
marker for genotype.
One inherent limitation to the post hoc analysis de-
scribed above was that only patients over the age of 5
years and only those without cognitive impairment were
included in the original phase II/III trial and extension
study. None of the patients with available genotype data
in these trials had a complete deletion/large rearrange-
ment (CD/LR); the genotype group most frequently as-
sociated with cognitive impairment, the hallmark of the
severe form of MPS II. The current paper expands the
analysis of the association between Abs, genotype, and
clinical outcomes by describing the results of a similar
analysis of an open-label clinical study (HGT-ELA-038;
NCT00607386) in which the primary objective was to
determine the safety of once-weekly intravenous dosing
of idursulfase 0.5 mg/kg in patients with MPS II up to
the age of 5 years with phenotypes ranging from attenu-
ated to severe [14]. Secondary endpoints included uGAG
levels, growth, liver size, and spleen size. The safety pro-
file of idursulfase in this study was similar to that seen
in previous clinical trials [15,16], and treatment was as-
sociated with decreases in uGAG levels, liver size, and
spleen volume. A total of 19/28 patients (67.9%) tested
positive for anti-idursulfase immunoglobulin G (IgG)
Abs at least one time point during the study. In this re-
port, we extend our investigation into the association be-
tween anti-idursulfase Ab status, genotype, and the
efficacy and safety of idursulfase via a post hoc analysis
of data from the 28 patients who were enrolled in HGT-
ELA-038.
Methods
Patients and study design
HGT-ELA-038 enrolled male patients ≤5 years of age at
screening with a clinically and biochemically confirmed
diagnosis of MPS II [14]. Exemptions to enter the study
were granted to 4 patients aged >5 years (6.5 years, 7.5
years, 6.3 years, and 6.2 years). These patients met all
other enrollment criteria. They had been identified at ≤5
years of age, but their study-site initiation was delayed
due to logistical issues in study start-up. Exclusion cri-
teria have been previously reported. Patients received
idursulfase 0.5 mg/kg by intravenous infusion every
week (±3 days) for 52 weeks. The population for the
current post hoc analysis was the safety population of
HGT-ELA-038, which included all enrolled patients who
received at least one dose or any portion of a dose of
idursulfase during the study.
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international guidelines and appropriate local country
regulations. Written informed consent was given by the
parents/guardians. The protocol and informed consent
documents were approved by the institutional review
board and/or independent ethics committee at each study
site. The work described in this manuscript represents
new statistical analyses of immunogenicity (antibody) test
results that were generated during HGT-ELA-038. No
new blood samples were obtained in order to perform the
current analyses, and no existing blood samples were re-
analyzed for Ab titer.
Ab measurements
As part of the HGT-ELA-038 study design, blood sam-
ples were screened by Shire Bioanalytics, Lexington,
MA, USA, for the detection of serum idursulfase IgG
Abs using the conformation-specific antibody (CSA) or
enzyme-linked immunosorbent (ELISA) assays [16]. All
samples meeting the CSA or ELISA cut points were con-
firmed by a radioimmunoprecipitation (RIP) assay. All
Ab+ samples were analyzed for NAbs with both an
in vitro activity-neutralizing assay [17] or a cell-based in-
ternalization assay [18].
Ab status
The following definitions were used for Ab status:
 Ab+: At least one serum specimen had measurable
anti-idursulfase IgG Ab by either CSA or ELISA,
confirmed by RIP, regardless of Ab status at any
subsequent visits. A patient was considered to be Ab+
at a given week if, by this time point, the patient had at
least one visit at which there were measurable Abs.
 Persistently Ab+ (PAb+): There were 3 or more
consecutive visits at which the patient was Ab+,
regardless of the Ab status at any subsequent visits.
A patient was considered to be PAb+ at a given
week if, by this time point, the patient had the first
of 3 or more consecutive visits at which there were
measurable IgG anti-idursulfase Abs.
 Neutralizing Ab+ (NAb+): At least one serum
specimen was positive at any time during the study
for NAbs on either the activity-NAb assay or a
cell-based internalization Ab assay, regardless of the
Ab status at any subsequent visits. A patient was
considered to be NAb+ at a given week if, by this time
point, the patient had at least one visit at which there
were measurable NAbs measured by either assay.
 Persistently NAb+ (PNAb+): There were 3 or more
consecutive visits at which the patient was NAb+,
regardless of NAb status at subsequent visits. A
patient was considered to be PNAb+ at a given week
if, by this time point, the patient had the first of 3 ormore consecutive visits at which there were
measurable NAbs by either the activity-NAb assay
or a cell-based internalization Ab assay.
 Antibody Negative (Ab−): A patient was considered
Ab− if all IgG anti-idursulfase Ab tests were negative
for the patient throughout the treatment period.
A patient was considered to be Ab− at a given week
if, by this time point, there were no previous visits
at which the patient had measurable IgG Abs, even
if the patient later became Ab+.
 Not PAb+: Patients did not meet the criteria to be
PAb+ at any time. Note that these patients could be
Ab−, Ab+, or NAb+.
 NAb Negative (NAb−): A patient had no positive
serum specimen during the study by either an
activity-NAb assay or a cell-based internalization Ab
assay. Note that these patients could be Ab−, Ab+,
or PAb+.
 Not PNAb+: Patients did not meet the criteria to be
PNAb+ at any time. Note that these patients could
be Ab−, Ab+ or NAb+.
Time point assignment for Ab status changes
Testing for anti-idursulfase Abs in HGT-ELA-038 was
performed using serum samples collected at baseline
and at scheduled visits for Study Weeks 9, 18, 27, 36, 45,
and 53. Note that Study Week visits in which idursulfase
infusions were administered were scheduled to occur at
7-day intervals; however, variations of ±3 days were per-
mitted for actual visit dates. Therefore, a Study Week
visit of a certain number (e.g., Week 27) for a given patient
may not have occurred at precisely the corresponding
number of calendar weeks after treatment start. The
protocol specified additional (unscheduled) sample collec-
tions if there was a suspicion of an IRAE. These unsched-
uled collections were assigned a time point in Calculated
Weeks by taking the date of the sample collection minus
the date of the baseline visit and dividing by 7.
Because Ab testing was performed at discrete time
points, the exact day on which a patient became Ab+
could not be determined. We used 2 guiding principles
to develop an algorithm to assign seroconversion dates.
First, all patients who became seropositive in our study
had done so by the first scheduled Ab sampling date at
the Study Week 9 visit. This meant that all patients be-
came seropositive at an unknown time point sometime
before the Study Week 9 visit. Second, it takes several
weeks to mount a measurable IgG response to a newly
introduced antigen [19].
Therefore, we developed an algorithm as follows:
 If there were no unscheduled, positive samples taken
before the Study Week 9 visit, then the date of
seroconversion was imputed to be Calculated Week
Pano et al. Orphanet Journal of Rare Diseases  (2015) 10:50 Page 4 of 144.5; that is, halfway between the date of the baseline
visit and the date of the Study Week 9 visit
(i.e., the first documented seropositive sample).
 If a patient had an unscheduled, positive sample
collection prior to Calculated Week 4.5, then the
patient was considered to have become positive on
the date of the sample collection. For example, if the
patient had an unscheduled, positive serum sample
at Calculated Week 3, then he was considered to
have seroconverted on that date.
 If the patient had an unscheduled, positive sample
collection after Calculated Week 4.5, but prior to
Study Week 9, then the patient was considered to
have become seropositive at the midpoint between
the last negative and first positive sample. If the
midpoint was before Calculated Week 4.5, however,
then Week 4.5 was assigned as the seroconversion
date. For instance, if a patient had an unscheduled,
positive sample at Study Week 5, then the patient
was considered to have become seropositive at
Calculated Week 4.5 (not at Week 2.5).
Safety assessments
In HGT-ELA-038, treatment-emergent adverse events
(TEAEs) were defined as adverse events (AEs) that oc-
curred on or after the first dose of idursulfase until 30
days after the completion of treatment. IRAEs were de-
fined as TEAEs that began on the day of the infusion or
the next day and were judged as possibly or probably re-
lated to the study drug. SAEs were defined as any TEAEs
that were life-threatening or resulted in death, inpatient
hospitalization, prolongation of existing hospitalization, a
persistent or significant disability/incapacity, or a congeni-
tal anomaly/birth defect. Important medical events that
may not result in death, be life-threatening, or require
hospitalization were considered to be SAEs when, based
upon appropriate medical judgment, they may have
jeopardized the patient and may have required medical or
surgical intervention to prevent one of the outcomes listed
above.
Efficacy assessments
Efficacy variables in HGT-ELA-038 included uGAG con-
centration, index of liver size (ILS), and spleen volume
as previously reported [14]. Urine samples for determin-
ation of uGAG levels and urine creatinine were collected
at baseline and at Study Weeks 18, 36, and 53. Urinary
GAG levels were normalized to urine creatinine and
were reported as μg GAG/mg creatinine. Abdominal
ultrasound examinations were conducted at local centers
at baseline and at Study Weeks 18, 36, and 53 to assess
the ILS [20]. With the patient in the supine position, the
section level of the liver in the anterior axillary line
(AAL [cm]), medioclavicular line (MCL [cm]), and theperpendicular section plane in the sternal line (STL [cm])
were measured 3 times. The ILS was calculated using the
following formula [20]: ILS (cm2) = 0.2618 * (AAL2 +
MCL2 + STL2). Spleen volume was assessed by abdominal
ultrasound examinations conducted at baseline and at
Study Weeks 18, 36, and 53. With the patient in the right-
recumbent position, the length (L), depth of length (DL),
breadth (B), and depth of breadth (DB) were also
measured 3 times (unit of measure: cm). The spleen vol-
umes were calculated using the following formula for an
ellipsoid [20]:
Spleen volume cm3
  ¼ 0:523  L  B  DL þ DBð Þ=2:
Data analysis: safety and efficacy outcomes by Ab status
Landmark analyses were performed to evaluate the rela-
tionship between anti-idursulfase IgG Abs and safety
outcomes. A landmark analysis divides patients into 2 or
more groups (e.g., PAb+ vs Not PAb+) at a fixed point in
time (the landmark point). These groups are then com-
pared prospectively on the basis of outcomes (e.g.,
IRAEs, SAEs) that occur subsequent to the landmark
point [21]. The median time to the first event after the
landmark point of Calculated Week 4.5 was estimated
using the Kaplan-Meier method and compared between
Ab status subgroups using the log-rank test. No analyses
were performed on Ab subgroups having fewer than 3
seropositive patients (~10% of the study population) for
that specific Ab status.
In some cases, a time-varying proportional hazards re-
gression (Cox) model was also used to assess the associ-
ation between Ab status and time to the first occurrence
of a specific AE. Patients who had no event were cen-
sored as of the time of their last visit. A relative risk
greater than 1 indicates that patients who have a positive
Ab status are at greater risk of the event than patients
who do not.
Event rate analyses were conducted to explore the re-
lationship between Ab status and AEs. Event rate ana-
lyses were stratified by Ab status. For a patient who was
always Ab−, the event rate was the number of events ob-
served divided by the total time on study (defined as U).
For a patient who became Ab+ during the study, T was
defined as the date of seroconversion as calculated fol-
lowing the algorithms described above. Using this defin-
ition for T, the negative period event rate is the total
number of events occurring prior to time T divided by
the total time on study while Ab− (time = T – 1 day).
The positive period event rate is the total number of
events that occurred at or after time T divided by the
time on study while Ab+ (U – T + 1 day).
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cacy outcomes, we compared ILS actual values, MCL z-
scores, spleen volumes, and normalized values for uGAG
at Study Weeks 18, 36, and 53 by Ab status at the land-
mark point as described above for landmark analyses
using the Wilcoxon rank sum test. Because genotype
may be related to both Ab status and efficacy outcomes,
we also conducted analyses of the percent change from
baseline in ILS, spleen volume, and uGAG concentration
at Week 53 by Ab status at the landmark point while
adjusting for genotype using analysis of covariance. This
was done to determine whether there was any residual
relationship between outcomes and Ab status beyond
that explainable by genotype.
Data analysis: safety and efficacy outcomes by genotype
Patients with available data were classified into the MS
group, the CD/LR group, or the frameshift/splice site
mutation (FS/SSM) group, defined as follows:
 MS: A mutation that results in nucleotide changes
in the IDS gene that introduces a single amino acid
residue change in the I2S enzyme.
 CD/LR: A mutation that results in complete
deletions or large rearrangements to the IDS gene.
 FS: A mutation that introduces a frame shift in the
IDS gene due to nucleotide deletions or insertions.
 SSM: A mutation that inserts or deletes a number of
nucleotides in the IDS gene in a specific site at
which splicing of an intron takes place during the
processing of precursor messenger RNA into mature
messenger RNA.
Note that one patient with the nonsense mutation
R443X, which leads to a stop codon in the ninth and final
exon of the IDS gene, was grouped into the MS group.
Safety outcomes were analyzed by genotype group to
explore the relationship between genotype and AEs. The
time to a first TEAE, SAE, or IRAE was calculated using
the Kaplan-Meier method [22].
For efficacy outcomes, the actual values for the ILS,
spleen volumes, and the actual normalized value for
uGAG, were summarized for each visit (baseline and
Study Weeks 18, 36, and 53) by genotype. Comparisons
between genotypes were assessed at each visit using the
Wilcoxon rank sum test for the observed value and an
analysis of covariance (ANCOVA) model with baseline
value included in the model as the covariate for change
and percent change from baseline.
Results
Study population and genotype
The details of the original study have been previously
published [14]. In brief, 28 patients aged 16 months to7.5 years (mean 4.0 years) were enrolled; one patient
(3.6%) discontinued after 4 weeks of treatment due to
compliance issues, but was followed for 16 weeks. The
mean age at diagnosis was 3.5 years (0.2–6.5 years).
There were no clear differences in age at diagnosis or at
enrollment between the patients who became Ab+ and
those who remained negative throughout the study.
Genotype data were available for 27 patients. Patients
were categorized into one of three groups based on
genotype (see Ab Status in Methods). These groups were
chosen based on the anticipated impact on endogenous
protein levels and functionality. The first group includes
patients with a CD/LR mutation. These patients lack the
IDS gene and produce no endogenous enzyme. It is
likely that an initial exposure to idursulfase could result
in a robust immune response since the enzyme would
be viewed as foreign by the body’s immune system. The
second group contains patients with FS/SSM. Such mu-
tations could be expected to lead to protein products
that range from those that are very short and non-
functional to those that are somewhat longer and may
retain some amount of residual enzyme activity. The
third group includes patients with MS, which would be
expected to produce some endogenous protein products
with varying degrees of integrity and functionality. We
anticipated that since the patients in the MS group have
had some exposure to I2S enzyme, albeit in very low
quantities and in mutated form, there would be a lower
incidence of an Ab response to idursulfase than would be
seen in the other genotype groups. Among the 27 patients
with genotype data, 8 were in the CD/LR group; 6 were in
the FS/SSM group; and 13 were in the MS group.
Ab status
An overall summary of Ab status is presented in Table 1.
When we analyzed Ab status by Study Week visit, we
found that all Ab+ and PAb+ patients had seroconverted
by Study Week 9, since PAb+ status was considered to
occur at the time of the first of 3 consecutive positive
serum samples. All patients who became NAb+, did so
by Study Week 27; and all those who became PNAb+,
did so by Study Week 36 (Figure 1). Of the 15 patients
who became NAb+ (Table 1), Abs from 14 displayed
neutralizing activity and Abs from all 15 displayed cellular
uptake inhibiting activity. The calculated time of serocon-
version was the landmark time used in all analyses.
Safety assessments and relationship with Abs status
IRAEs
We performed a landmark analysis to determine
whether Ab status was associated with a shorter time to
first IRAE after the landmark point (see Data Analysis in
Methods). Only patients who were IRAE-naïve at the
landmark point were included because the risk of IRAEs
Table 1 Overall Ab status and relationship between IgG and NAbs in the primary analysis population
N (%) Ab+ (n = 19) PAb+ (n = 16) NAb+ (n = 15) PNAb+ (n = 14) Total (n = 28)
Ab+ – 16 (100) 15 (100) 14 (100) 19 (68)
PAb+ 16 (84) – 14 (93) 14 (100) 16 (57)
NAb+ 15 (79) 14 (88) – 14 (100) 15 (54)
PNAb+ 14 (74) 14 (88) 14 (93) – 14 (50)
Ab+, antibody positive; IgG, immunoglobulin G; NAb+, neutralizing antibody positive; PAb+, persistently antibody positive; PNAb+, persistently neutralizing
antibody positive.
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sures are implemented after a first IRAE. We found that
PAb+ patients were no more likely to experience future
IRAEs than were Not PAb+ patients (p = 0.90, Figure 2).
Similar results were seen for Ab+ vs Ab − patients (p =
0.46); NAb+ vs NAb− patients (p = 0.52); and PNAb+ vs
Not PNAb+ patients (p = 0.52).
Next, an IRAE event rate analysis revealed several in-
teresting patterns. First, IRAE event rates were lowest
among patients who were always Ab− during the study
(0.014 events/week, 95% CI: 0.004–0.024 events/week).
Second, as expected, the IRAE event rate fell over time
for all Ab status groups, likely due to preventive mea-
sures implemented after a first IRAE as described above.
The third pattern we observed was that, among patientsFigure 1 Ab+, PAb+, NAb+, and PNAb+ percentages of total
subjects by Study Week visit in the primary analysis population.
Percent of total subjects that are Ab+, PAb+, NAb+, and PNAb+ by
Study Week visit in the primary analysis population. For the Ab+,
and NAb+ patients, the percentage of patients who have Abs or
NAbs, respectively, at that particular study visit are given. For PAb+
and PNAb+ patients, the cumulative percentage of patients is
shown. A patient was considered to be PAb+ or PNAb+ at a given
week if, by this time point, the patient had the first of 3 or more
consecutive visits at which there were measurable anti-idursulfase
Abs/NAbs. Ab+, antibody positive; NAb+, neutralizing antibody positive;
PAb+, persistently antibody positive; PNAb+, persistently neutralizing
antibody positive.who developed Abs, the event rates were highest before
those Abs developed. For example, the rate was 0.239
events/week (95% CI: 0.125–0.352 events/week) for
eventual Ab+ patients during the period before becom-
ing Ab+ and 0.036 events/week (95% CI: 0.024 – 0.048)
after becoming Ab+. Similar results were seen for PAb+,
NAb+, and PNAb+ patients (data not shown). These
findings suggest that rather than Abs being the cause of
IRAEs, certain patients may intrinsically possess a char-
acteristic that predisposes them to both Ab formation
and IRAEs.
TEAEs and SAEs
The majority of TEAEs and SAEs in this study were
considered to be related to manifestations commonly
seen in patients with MPS II (e.g., respiratory infections).
All patients experienced TEAEs, and the event rate did
not significantly differ according to Ab status (data not
shown). We conducted landmark analyses to determine
whether the time to a first TEAE after the landmark
point differed by Ab status at the landmark point, but
we found no significant differences (data not shown).Figure 2 Kaplan-Meier plot of time to the first IRAE after the
landmark point for patients with no IRAEs prior to the landmark
point, by PAb status at the Study Week 9 visit. IRAE, infusion-related
adverse event; PAb+, persistently antibody positive; PAb−, persistently
antibody negative.
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model found that Ab status was not associated with any
statistically significant overall increase in TEAE risk
(data not shown).
The SAE rates were low overall. A total of 13/28 pa-
tients (46.4%) experienced a total of 38 SAEs (Table 2)
in study HGT-ELA-038. Of these, 4 patients (14.3%) re-
ported 10 SAEs that were considered possibly or prob-
ably related to the study drug; all of these SAEs were
also IRAEs. All of the events were considered by the in-
vestigators to be mild or moderate in severity. The pro-
portion of patients with at least one SAE was always
slightly, but not statistically significantly, higher in the
groups with an Ab+ status (Ab+, PAb+, Nab+) than in
the corresponding Ab− groups. Landmark analyses indi-
cated that the time to the first SAE after the estimated
time point of seroconversion was numerically shorter for
patients with a positive Ab status, but again the differ-
ences were not statistically significant. Note that in the
landmark analyses, only those first SAEs which occurred
after the landmark (28 SAEs out of 38 total) were con-
sidered. The time-varying proportional hazards (Cox)
model found that, although patients with a positive Ab
status had a numerically higher risk of SAEs than their
Ab− counterparts, these differences were not statistically
significant (data not shown).Relationship between genotype group, Ab status, and risk
of IRAEs and SAEs
We next examined the association between genotype,
the development of Abs, and the risk of IRAEs or SAEs.
We found that patients in the CD/LR group were the
most likely to develop Abs, while patients in the MS
group were the least likely to develop Abs (Table 3). In-
deed, patients who remained Ab− throughout the study
were only found in the MS group. These Ab status differ-
ences were statistically significant for the CD/LR group vs
the MS group (p ≤ 0.005 for each of Ab+, PAb+, NAb+,
and PNAb+), as well as for the MS group vs the FS/SSM
group (p < 0.05 for all, except PAb+). The differences be-
tween the CD/LR and FS/SSM groups in regards to Ab
status were not statistically significant.
We calculated the overall cumulative probability of pa-
tients having at least one IRAE by genotype group and
found that, by end of study, it was highest for patients in
the CD/LR group (87.5%) and lower for patients in the
FS/SSM group (50.0%) or the MS group (46.2%). When
we compared the time to development of a first IRAE
among genotype groups, we found that the time was
significantly shorter for the CD/LR group than it was
for the MS group (p = 0.004). However, we found no
statistically significant differences in the time to devel-
opment of a first IRAE when we compared the FS/SSMgroup with either the CD/LR (p = 0.11) or the MS
group (p = 0.86).
For SAEs, the cumulative probability of having at least
one SAE by genotype group was highest for the CD/LR
and the FS/SSM groups (75.0% each) and lowest for the
MS group (15.4%). When we compared the time to de-
velopment of a first SAE among groups, we found that
the time was significantly shorter for the CD/LR (p =
0.003) and FS/SSM groups (p = 0.007) than it was for the
MS group.
These findings indicate that the CD/LR genotype is as-
sociated with the highest risk of IRAEs and SAEs. Be-
cause all patients with this genotype invariably
developed Abs (Table 3), any apparent IRAE and SAE
risk differences observed in the analysis by Ab status
may be confounded by this association. Additionally,
many SAEs were related to MPS II disease progression.
It is plausible that patients with the CD/LR genotype
simply had a higher disease burden, which manifested as
SAE-qualifying events. This is supported by the fact that
when the time-varying proportional hazards (Cox)
model for risk of a first SAE by Ab status (see TEAEs
and SAEs, above) was adjusted for genotype, the numer-
ically greater (but not statistically significant) risk associ-
ated with positive Ab status was no longer apparent.
Efficacy assessments by Ab status and genotype group
Liver size
To examine the relationship between Ab status and liver
size during idursulfase treatment, we compared the
mean ILS score over time by Ab status at the landmark
point. All patient groups experienced an initial decrease in
mean ILS score after treatment start (Figure 3A). PAb+ pa-
tients had a larger mean observed ILS score at Week 53
than did Not PAb+ patients (p = 0.025). Similar results
were seen for Ab+ vs Ab− (p = 0.008), NAb+ vs NAb−
(p = 0.001), and PNAb+ vs Not PNAb+ (p = 0.001) patients
(data not shown).
Because genotype may be related to both Ab status
and efficacy outcomes, percent change from baseline in
ILS at Week 53 was also compared between Ab status
groups, adjusted for genotype using analysis of covari-
ance. This was done to determine whether there was any
residual relationship between liver size outcome and Ab
status beyond that explainable by genotype. After adjust-
ment for genotype, only the comparisons involving NAb
status groups remained significant at Week 53 (Ab+ vs
Ab− adjusted p = 0.365; PAb+ vs. Not PAb+ adjusted
p = 0.193; NAb+ vs NAb− adjusted p < 0.001; PNAb+ vs
Not PNAb+ adjusted p < 0.001; data not shown).
To assess the relationship between genotype and liver
size during treatment with idursulfase, we plotted the
mean observed ILS score over time by genotype and
found that it decreased over time in all genotypes, with
Table 2 SAEs by patient
Patient information SAE information
ID Genotype group Ab status overall Preferred term Relationship to study drug IRAE Included in landmark analyses?a
1 FS/SSM PNAb+ Bronchopneumonia Not related No Yes
Bronchospasm Not related No Yes
2 CD/LR PAb+ Respiratory distress Probably related Yes Nob
Pulmonary hypertension Not related No Yes
3 MS Ab− Bronchopneumonia Not related No Yes
Hypoxia Not related No Yes
Respiratory distress Not related No Yes
4 FS/SSM PNAb+ Microcytic anemia Not related No Yes
Pneumonia Not related No Yes
5 CD/LR PNAb+ Rash Probably related Yes Nob
Pyrexia Probably related Yes Nob
Pyrexia Probably related Yes Yes
Pyrexia Probably related Yes Noc
Pyrexia Probably related Yes Noc
Irritabilityd Not related No Yes
6 MS Ab− Skin hypertrophy Not related No Yes
7 CD/LR PNAb+ Urticaria Possibly related Yes Nob
Pyrexia Possibly related Yes Nob
Urticaria Possibly related Yes Nob
Respiratory tract infection Not related No Yes
Respiratory tract infection Not related No Noc
Ear infection Not related No Yes
Viral pharyngitis Not related No Yes
Pneumonia Not related No Yes
Urticaria Not related No Yes
Atonic seizures Not related No Yes
Edema peripheral Not related No Yes
8 FS/SSM Ab+ Gastrointestinal infectiond Not related No Yes
9 Unknown PNAb+ Food poisoningd Not related No Yes
Upper respiratory tract infection Not related No Yes
Muscle contracture Not related No Yes
10 CD/LR PNAb+ Pyrexiad Probably related Yes Yes
11 CD/LR PNAb+ Asthma Not related No Yes
Bronchopneumonia Not related No Yes
Otitis media Not related No Yes
12 CD/LR PNAb+ Hematoma Not related No Yes
13 FS/SSM PNAb+ Catheter site hematoma Not related No Nob
Otitis media Not related No Yes
Ab+, antibody positive; Ab−, antibody negative; CD/LR, complete deletion/large rearrangement; FS/SSM, frameshift/splice site mutation; IRAE, infusion-related
adverse event; landmark, estimated time point of change in Ab status; MS, missense mutation; PAb+, persistently antibody positive; PNAb+, persistently
neutralizing antibody positive, SAEs, serious adverse events.
aOnly 28 of the 38 total SAEs that occurred during HGT-ELA-038 were included in the landmark analyses investigating the relationship between Ab status,
genotype, and risk of SAEs. SAEs were excluded from the landmark analyses if they occurred before the landmark point (the estimated time point of change in
Ab status; see Methods) or if they were not the first occurrence of an SAE for a given patient.
bOccurred before the landmark point.
cNot the first occurrence for this patient.
dPatients were hospitalized for social reasons (i.e., convenience) rather than for medical reasons.
Pano et al. Orphanet Journal of Rare Diseases  (2015) 10:50 Page 8 of 14
Table 3 Ab status at end of study by genotype class (n = 27)a
Mutation group, n (%) Statistical comparison
Ab status CD/LR (n = 8) FS/SSM (n = 6) MS (n = 13) CD/LR vs FS/SSMb CD/LR vs MSb FS/SSM vs MSb
Ab+ 8 (100) 6 (100) 4 (31) p = 1.000 p = 0.005 p = 0.011
PAb+ 8 (100) 4 (67) 3 (23) p = 0.165 p = 0.001 p = 0.129
NAb+ 7 (88) 5 (83) 2 (15) p = 1.000 p = 0.002 p = 0.010
PNAb+ 7 (87.5) 4 (66.7) 2 (15.4) p = 0.538 p = 0.002 p = 0.046
Ab+, antibody positive; CD/LR, complete deletion/large rearrangement; FS/SSM, frameshift/splice site mutation; MS, missense mutation; NAb+, neutralizing antibody
positive, PAb+; persistently antibody positive; PNAb+, persistently neutralizing antibody positive.
aGenotype data not available for one patient enrolled in HGT-ELA-038.
bp-value from Fisher’s exact test.
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group (Figure 3B). At Week 53, the mean observed ILS
score was significantly lower for the FS/SSM group than
it was for the MS group (p = 0.049). Other comparisons
between genotype groups at Week 53 were not statisti-
cally significant. The mean percent changes from base-
line in ILS scores at Week 53 were −10.1% for the
CD/LR group, 1.6% for the FS/SSM group, and −27.5%
for the MS group. The difference was statistically signifi-
cant for the CD/LR group vs the MS group (p = 0.030)
and for the FS/SSM group vs the MS group (p = 0.013),
but was not statistically significant for the CD/LR group
vs the FS/SSM group (p = 0.64).Spleen volume
We compared the mean spleen volume over time by Ab
status at the landmark point. All patient groups regardless
of Ab status experienced an initial decrease in mean ob-
served spleen volume on treatment (Figure 4A). In contrast
to the results seen for the ILS, the decrease in mean ob-
served spleen volume was maintained to the end of the
study, except for in the PNAb+ group, in which there was a
slight upswing at Week 53. At the majority of time points,
the mean observed spleen volume was slightly higher in the
PAb+ group than in the PAb− group, but this difference
was not statistically significant (p = 0.25 at Week 53). Simi-
lar results were seen for the Ab+ vs Ab− (p = 0.14), NAb+
vs NAb− (p = 0.41), and PNAb+ vs Not PNAb+ (p = 0.23)
groups at Week 53 (data not shown).
In the genotype analysis, the mean spleen volume at
Week 53 was similar between the CD/LR and the MS
genotype groups, but larger in the FS/SSM group
(Figure 4B). The difference was statistically significant
for the CD/LR group vs the FS/SSM group (p = 0.034)
and for the FS/SSM group vs the MS group
(p = 0.002), but the difference was not statistically
significant for the CD/LR group vs the MS group
(p = 0.23). The mean percent change from baseline in
spleen volume was −25.3% for the CD/LR group, −2.2%
for the FS/SSM group, and −23.7% for the MS group. The
difference was statistically significant for the CD/LR groupvs the FS/SSM group (p = 0.040) and for the FS/SSM
group vs the MS group (p < 0.001), but the difference was
not statistically significant for the CD/LR group vs the MS
group (p = 0.69).Urinary GAG level
All patients experienced decreased uGAG levels after initi-
ation of idursulfase treatment (Figure 5A). A landmark ana-
lysis performed by PAb status at the landmark point
showed that patients who became PAb+ had a statistically
significantly higher mean uGAG level than did their PAb−
counterparts at Week 53 (p = 0.002). Similar results were
seen for Ab+ vs Ab− (p = 0.033), NAb+ vs NAb− (p <
0.001), and PNAb+ vs Not PNAb+ patients (p < 0.001) at
Week 53 (data not shown).
As was done for liver size, percent change from base-
line in uGAG concentration at Week 53 was also com-
pared between Ab status groups as adjusted for
genotype using analysis of covariance. This was done to
determine whether there was any residual relationship
between uGAG level and Ab status beyond that explain-
able by genotype. After adjustment for genotype, only
the comparisons involving NAb status groups remained
significant at Week 53 (Ab+ vs Ab- adjusted p = 0.426;
PAb+ vs Not PAb+ adjusted p = 0.231; NAb+ vs NAb-
adjusted p = 0.002; PNAb+ vs Not PNAb+ adjusted p =
0.004; data not shown).
The genotype analysis (Figure 5B) showed that the mean
uGAG level at Week 53 was significantly higher for the
CD/LR group than it was for the MS group (p = 0.015).
The difference in the mean uGAG level at Week 53 was
not significant for the CD/LR group vs the FS/SSM group
(p = 0.21) or for the FS/SSM group vs MS group
(p = 0.28). The mean percent change in uGAG level from
baseline (adjusted for baseline values) was −40.5% for the
CD/LR group, −57.3% for the FS/SSM group, and −62.6%
for the MS group. The difference was statistically signifi-
cant for the CD/LR group vs the MS group (p = 0.004),
but the difference was not significant for the CD/LR group
vs the FS/SSM group (p = 0.080) or for the FS/SSM group
vs the MS group (p = 0.29).
Figure 3 The ILS over time by PAb status and genotype group. A)
ILS over time by PAb status at the landmark point. Week 53, PAb+ vs
PAb−, p = 0.025. B) ILS over time by genotype group. Week 53, FS/
SSM vs MS, p = 0.049. CD/LR, complete deletion/large rearrangement;
FS/SSM, frameshift/splice site mutation; ILS, index of liver size; MS,
missense mutation; PAb+, persistently antibody positive; PAb−,
persistently antibody negative.
Figure 4 Spleen volume over time by PAb status and genotype
group. A) Spleen volume over time by PAb status at the landmark
point. There are no statistically significant differences at any time
point. B) Spleen volume over time by genotype group. Week 0, FS/
SSM vs MS, p = 0.007. Week 18, FS/SSM vs MS, p = 0.007. Week 36,
FS/SSM vs MS, p = 0.002. Week 53, FS/SSM vs MS, p = 0.002. Week 53,
CD/LR vs FS/SSM, p = 0.034. CD/LR, complete deletion/large
rearrangement; FS/SSM, frameshift/splice site mutation; MS, missense
mutation; PAb+, persistently antibody positive; PAb−, persistently
antibody negative.
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Enzyme replacement therapy in lysosomal storage diseases
leads to production of Abs in fractions of the populations
that range from about 2–15% (Gaucher disease), to
95–100% (MPS IV and Pompe disease) [10,23]. Purely
descriptive analyses of Ab formation in patient groups
cannot answer the question of whether the presence of
Abs has clinical significance, and if so, what type of strat-
egies should be implemented to mitigate this impact. In
Pompe disease, for instance, a subgroup of patients
(CRIM-negative) develop high-titer NAbs, which are
clearly associated with worse clinical outcomes [9]. In thisparticular population, immunomodulatory regimens are
now becoming standard of care, in order to prevent the
production of Abs and ensure a good therapeutic response
[24]. In MPS IV, initiation of ERT leads to a universal Ab
response, but there appears to be no correlation between
Ab titer and clinical outcomes [10]. In Fabry disease, there
appears to be no correlation between titers of anti-drug
Abs and the onset of clinical events, glomerular filtration
rate, or plasma biomarkers [25].
Figure 5 Urinary GAG levels over time by PAb status and genotype
group. A) Urinary GAG levels over time by PAb status at the
landmark point. Weeks 18 and 36, PAb+ vs PAb−, p < 0.001. Week 53,
PAb+ vs PAb−, p = 0.002. B) Urinary GAG levels over time by
genotype group. Week 18, CD/LR vs MS, p = 0.01. Week 36, CD/LR vs
MS, p = 0.005. Week 53, CD/LR vs MS, p = 0.015. There were no other
significant differences between groups. CD/LR, complete deletion/
large rearrangement; FS/SSM, frameshift/splice site mutation; MS,
missense mutation; PAb+, persistently antibody positive; PAb−,
persistently antibody negative; uGAG, urinary glycosaminoglycan.
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showed no association between Ab status and safety or
efficacy outcomes. That study; however, had only
enrolled patients with the attenuated form of the disease,
and consequently there were no patients with the
CD/LR genotype included in the analysis. We have now
expanded our investigation to include a population of
pediatric MPS II patients with the severe phenotype andCD/LR genotype. In HGT-ELA-038, 28 treatment-naïve
MPS II patients who were ≤5 years of age at screening
received 0.5 mg/kg of idursulfase weekly for 52 weeks
[14]. In our current post hoc analysis of the HGT-ELA-
038 data, we have rigorously examined the relationship
between anti-idursulfase Ab status, genotype, and safety
and efficacy outcomes by distinguishing between events
happening prior to and after seroconversion.
We have demonstrated that there is an association be-
tween genotype and Ab response in this cohort. Patients
with the CD/LR genotype were more likely to develop
an immune response to idursulfase than were the pa-
tients with the MS genotype (Table 3). Patients with the
FS/SSM genotype fell between the other 2 genotype
groups. These results make biological sense: patients
who produce no enzyme at all are more likely to develop
an immune response following idursulfase treatment
than are those patients with a milder mutation that pro-
duces a truncated protein or a protein with a single
amino acid substitution. With no endogenous enzyme,
idursulfase would be viewed as a foreign, non-self pro-
tein by the body.
The safety data were analyzed both by Ab status and
by genotype. Antibody status was not associated with
time to a first TEAE or SAE after the landmark point,
nor was Ab status associated with any statistically sig-
nificant overall increase in TEAE or SAE risk. For SAEs,
several statistical methods indicated that the risk of
SAEs was higher in patients who developed Abs, but the
differences were not statistically significant. It is interest-
ing to note that the majority of SAEs in this study could
be considered disease-related, such as respiratory infec-
tions. Only 10 of the 38 SAEs (26%) were considered at
least possibly related to study drug. All 10 SAEs were
also IRAEs and were reported by only 4 patients, all of
whom were in the CD/LR genotype group (Table 2).
Therefore, the numerically higher cumulative probability
of developing an SAE in the CD/LR group compared
with the MS group may reflect the more serious disease
pathology in the former group. Because the patients with
the CD/LR genotype invariably developed Abs (Table 3),
any apparent increase in risk for SAEs associated with
Abs could be explained by the more severe underlying
disease phenotype that is driven by genotype.
There did not seem to be an association between Ab+
status and risk of IRAEs. For IRAEs, landmark analyses
among patients who were IRAE-naïve at the landmark
point found that patients with any type of positive Ab
status were no more likely to experience future IRAEs
than were patients who did not have that positive Ab
status (Figure 2). The event rate for IRAEs was higher
for patients who became Ab+ than it was for those who
remained negative throughout the study. Of interest, the
rate was highest during the Ab− period, and then decreased
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PAb+ or PNAb+. A similar phenomenon was seen in our
previous post hoc analysis of older patients with the attenu-
ated form of MPS II [11]. This effect is likely due to the
implementation of preventive measures [13] after a first
IRAE rather than any protective effect of Abs. This pattern
suggested that certain genotypes, an intrinsic factor, may
predispose patients to both Ab formation and to IRAEs,
rather than Abs being the cause of IRAEs. Indeed, at the
end of the study, the cumulative probability of having at
least one IRAE was highest for patients in the CD/LR
group (87.5%) and lowest (46.2%) for patients in the MS
group, with a shorter time to development of a first IRAE
for CD/LR patients than for MS patients (p = 0.004).
Notably, all 4 patients who reported IRAEs that qualified as
SAEs were in the CD/LR group.
Efficacy variables were also analyzed by Ab status and
genotype. All patient groups experienced an initial de-
crease in liver size after initiation of idursulfase. Overall,
Ab+, PAb+, NAb+, and PNAb+ patients demonstrated
an upswing in liver size toward the end of the study
(Study Week 53), returning to approximately baseline
values (Figure 3A), and the differences were significant.
To determine whether there was any residual relation-
ship between liver size outcome and Ab status beyond
that explainable by genotype, the percent change from
baseline in ILS at Week 53 was also compared between
Ab status groups as adjusted for genotype using analysis
of covariance. After adjustment for genotype, only the
comparisons between NAb status groups remained signifi-
cant. In the genotype-based analysis, patients in the
CD/LR and FS/SSM groups had a less pronounced
decrease in liver size than did those in the MS group
(Figure 3B). The CD/LR and FS/SSM groups also tended
to return towards baseline values at the end of the study.
For spleen size, all patient groups also experienced a
decrease in spleen size after initiation of idursulfase.
Unlike for liver size, Ab status had no statistically signifi-
cant association with the spleen size response (Figure 4A).
In the genotype analysis, the mean spleen volume at Week
53 was similar between the CD/LR and the MS genotype
groups, but significantly greater in the FS/SSM group than
in either of the other groups (Figure 4B). These results
suggest that Ab status and genotype may influence the
degree of liver size response to idursulfase and that
genotype may influence the degree of spleen size response
to idursulfase.
Urinary GAG levels fell after the initiation of idursulfase
for all patient groups, but patients with Ab+, PAb+, NAb+,
and PNAb+ status had a less robust uGAG decline in the
latter part of the study than did their Ab− counterparts
(Figure 5A). As with liver size; however, comparisons
between Ab status groups for the percent change from
baseline in uGAG level at Week 53 only remainedsignificant for NAb status groups after adjustment for
genotype. The comparisons between the Ab+ and Ab−
groups and PAb+ and Not PAb− groups were no longer
significant. In the genotype-based analysis, patients in the
CD/LR genotype group had a less pronounced decrease in
uGAG levels than did patients in the MS group (Figure 5B).
Overall, the efficacy of idursulfase as measured by signifi-
cantly decreased uGAG levels from baseline was main-
tained over the course of the study. The continued
association of NAbs with poorer outcome measures
suggest that NAbs, as expected, are effective at inactivating
I2S, thereby reducing the effect of idursulfase therapy.
There are a number of limitations to our data analyses
that are inherent to the study design. First, although this
is one of the largest cohorts of MPS II patients that has
been studied for the association between genotype, Ab
status, and safety outcomes, the numbers are still small.
Conclusions should be considered with this fact in mind.
Second, the exact time of each patient’s seroconversion
was not known. Therefore, we assigned seroconversion
dates according to the algorithm described in the
Methods. The choice of the assignment date of Calcu-
lated Week 4.5 was made based on the fact that it takes
several weeks for an Ab response to develop after expos-
ure to a new antigen [19]. Calculated Week 4.5 was thus
halfway between first exposure (baseline) and Study
Week 9, at which time point all patients who would be-
come Ab+ in this study had done so. In some cases, data
indicating that a patient had seroconverted prior to
Calculated Week 4.5 were available because of an
unscheduled sampling taken after an IRAE. In those
cases, the earlier time point—the date of the unscheduled
sampling—was used as the seroconversion date. Third,
MPS II is a complex multi-systemic disease; therefore,
many of the observed SAEs may be related to the
underlying disease and not necessarily to a drug effect,
which further complicates the interpretation of drug safety
data in this population.
Conclusions
We have rigorously examined the relationship between
anti-idursulfase Ab status, genotype, and safety and effi-
cacy outcomes for MPS II patients aged ≤5 years at
screening who were treated with idursulfase as part of
study HGT-ELA-038. Our data support the idea that pa-
tient genotype is associated with the risk of an immune
response to idursulfase. Patients in the CD/LR group
were the most likely to develop Abs, while patients in
the MS group were the least likely to develop Abs. Our
study also provides evidence that patient genotype, but
not Ab status, is associated with the overall safety of
idursulfase treatment. A CD/LR genotype appeared to
be associated with an increased risk of IRAEs and SAEs
when compared with the MS genotype. Therefore, any
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outcomes are most likely influenced by genotype. Both
NAbs and genotype seem to be associated with a less
robust efficacy response to idursulfase treatment at
Week 53 in terms of liver size and uGAG level. In
contrast, genotype alone appeared to be associated with
spleen size outcome on idursulfase treatment.
We would like to emphasize that the associations
between Ab formation, genotype, and efficacy outcomes
were not universally observed. For example, individual
patients with a CD/LR genotype and high Ab titers could
still experience a large decrease in liver size, spleen size, or
uGAG level. Because of this observation, genotype and Ab
status appear to have limited value in predicting a patient’s
clinical response and must be interpreted with caution. As
in our previous post hoc analysis of data from the phase
II/III trial and extension study of idursulfase in attenuated
MPS II patients over 5 years of age [11], our data do not
suggest specific recommendations or modifications be
made to the current treatment guidelines associated with
the use of idursulfase.
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